# A Study to Investigate the Efficacy, Safety, and Tolerability of JNJ-42165279 in Adolescent and Adult Participants With Autism Spectrum Disorder

> **NCT03664232** · PHASE2 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 78 (actual)

## Conditions studied

- Autism Spectrum Disorder

## Interventions

- **DRUG:** JNJ-42165279
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03664232
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-07
- **Primary completion:** 2022-10-17
- **Final completion:** 2022-10-28
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2025-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03664232

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03664232, "A Study to Investigate the Efficacy, Safety, and Tolerability of JNJ-42165279 in Adolescent and Adult Participants With Autism Spectrum Disorder". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03664232. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*